Cumberland Pharmaceuticals Inc (CPIX)

4.45
NASDAQ : Health Care
Prev Close 4.65
Day Low/High 4.43 / 4.52
52 Wk Low/High 4.20 / 6.50
Avg Volume 10.80K
Exchange NASDAQ
Shares Outstanding 16.23M
Market Cap 75.45M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Insider Trading Alert - KPTI, CPIX And LB Traded By Insiders

Insider Trading Alert - KPTI, CPIX And LB Traded By Insiders

Stocks with insider trader activity include KPTI, CPIX and LB

Cumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For Systemic Sclerosis

Cumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For Systemic Sclerosis

- FDA clears investigational new drug submission

Caldolor® Launched For The Treatment Of Pain And Fever In Children

Caldolor® Launched For The Treatment Of Pain And Fever In Children

-Follows Recent FDA Approval for Caldolor's Pediatric Indication

Bearish Bets: Pharma, Financial and Retail Stocks That Look Good Short

JLL, TCO, PFE, VIPS and CPIX were all recently downgraded by TheStreet’s Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CMO, ETN, INTL, JCP, PCAR, POWI, WRE Downgrades: AIZ, CPIX, JAH, LBRDA, LBRDK, LOV, ONE, PFE, PRMW, SPAR, TRR, VIPS Initiations: DRIO, LMRK Read on to get TheStreet Quant Ratings' detailed report:

Vaprisol Dose Comparison Published Supporting Its Efficacy, Safety And Pharmacokinetics

Vaprisol Dose Comparison Published Supporting Its Efficacy, Safety And Pharmacokinetics

Vaprisol demonstrates favorable efficacy and safety profile with over 70% of patients reaching treatment goal

Piramal Critical Care And Cumberland Pharmaceuticals Announce Launch Of Caldolor And Vaprisol Co-Promotion

Piramal Critical Care And Cumberland Pharmaceuticals Announce Launch Of Caldolor And Vaprisol Co-Promotion

- Piramal Critical Care begins promoting Cumberland's Caldolor® and Vaprisol® brands

Caldolor® Launched In Australia For Treatment Of Pain And Fever

Caldolor® Launched In Australia For Treatment Of Pain And Fever

New injectable formulation of ibuprofen for Australia

Caldolor Approved For Use In Pediatric Patients

Caldolor Approved For Use In Pediatric Patients

Caldolor® (ibuprofen) Injection Approved in Pediatric Patients Six Months and Older for Management of Pain and Reduction of Fever

Cumberland Pharmaceuticals And Piramal Enterprises Announce Co-Promotion Agreement

Cumberland Pharmaceuticals And Piramal Enterprises Announce Co-Promotion Agreement

- Piramal Critical Care to promote Cumberland's Caldolor® and Vaprisol® brands

New Caldolor Integrated Safety Analysis Published Supporting The Safety Of Caldolor® (ibuprofen) Injection

New Caldolor Integrated Safety Analysis Published Supporting The Safety Of Caldolor® (ibuprofen) Injection

Caldolor demonstrates favorable safety profile with cumulative analysis of clinical data

Cumberland Pharmaceuticals And Clinigen Group Announce Strategic Alliance

Cumberland Pharmaceuticals And Clinigen Group Announce Strategic Alliance

Marketing and distribution agreement will provide Cumberland Pharmaceuticals' access to new international markets and strengthen Clinigen's North American footprint

Insider Trading Alert - CPIX, ORA And SLAB Traded By Insiders

Insider Trading Alert - CPIX, ORA And SLAB Traded By Insiders

Stocks with insider trader activity include CPIX, ORA and SLAB

Insider Trading Alert - CPIX, GWRE And ADVS Traded By Insiders

Insider Trading Alert - CPIX, GWRE And ADVS Traded By Insiders

Stocks with insider trader activity include CPIX, GWRE and ADVS

Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones

Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones

- Initial Hepatoren® Phase II study results